Glucagon (19-29),human
Cat.No:CLP1562 Solarbio
CAS:64790-15-4
Purity:≥95%
Appearance:Lyophilized powder
Storage:Store at -20℃,2 years.(Avoid freeze/thaw cycles)
Qty:
Size:
{{cart_num}}
My CartCAS:64790-15-4
Purity:≥95%
Appearance:Lyophilized powder
Storage:Store at -20℃,2 years.(Avoid freeze/thaw cycles)
Qty:
Size:
Product Type | Peptides |
CAS | 64790-15-4 |
Sequence(1LC) | AQDFVQWLMNT |
Sequence(3LC) | Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr |
Molecular Formula | C61H89N15O18S1 |
Molecular Weight | 1352.53 |
Purity | ≥95% |
Appearance | Lyophilized powder |
Solubility | DMSO:≥ 25 mg/mL; *Ultrasonic solubilization; |
Salt Form | Trifluoroacetate salt |
Source | Synthetic |
Storage | Store at -20℃,2 years.(Avoid freeze/thaw cycles) |
Category/Label | Hormone and Related Peptides |
Background | Glucagon (19-29), human is a potent and efficient inhibitor of insulin secretion. |
In Vitro | Glucagon (19-29), from 0.1 pM to 1 nM, exerts a potent negative inotropic action. The most striking observation is a 45% increase in the amplitude of cell contractility elicited by the combination of 30 nM glucagon with 1 nM Glucagon (19-29). |
In Vivo | Glucagon (19-29), also named Miniglucagon, is the COOH-terminal (19-29) fragment processed from glucagon. Glucagon (19-29) dose-dependently inhibits insulin secretion stimulated by 8.3 M glucose, with no change in the perfusion flow rate. A concentration of 1 nM Glucagon (19-29) has a significant inhibitory effect on a 1 nM glucagon-like peptide 1 (7-36) amide–potentiated insulin secretion. Glucagon (19-29) is a highly potent and efficient inhibitor of insulin release by closing, via hyperpolarization, voltage-dependent Ca2+ channels linked to a pathway involving a pertussis toxin-sensitive G protein. |
Reference | [1]. Dalle S, et al. Miniglucagon (glucagon 19-29), a potent and efficient inhibitor of secretagogue-induced insulin release through a Ca2+ pathway. J Biol Chem. 1999 Apr 16;274(16):10869-76. [2]. Dalle S, et al. Miniglucagon (glucagon 19-29): a novel regulator of the pancreatic islet physiology. Diabetes. 2002 Feb;51(2):406-12. [3]. Pavoine C, et al. Miniglucagon [glucagon-(19-29)] is a component of the positive inotropic effect of glucagon. Am J Physiol. 1991 May;260(5 Pt 1):C993-9. |
Unit | Bottle |
Specification | 1mg 5mg |
Remark:These protocols are for reference only. Solarbio does not independently validate these methods.
Note:
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.